Experimental design and bacterial antigen-specific immune responses.

<p>A) C57BL/6 mice were randomized to control vs. cancer groups. The cancer group received a subcutaneous injection of Pan02 cells. Following 3 weeks, all mice were given an IV injection of transgenic (Tg) T cell receptor (TCR) CD8⁺Thy1.1⁺ T cells. After 24 hours, uninfected mice were sacrificed for the day 0 time point, and all other mice were given an intraperitoneal injection of LM-OVA and underwent spleen collections at days 5 and 14 post-infection. B) At days 5 or 14 following infection, there were no significant differences in antigen-specific CD8+T cells expansion between the control and cancer groups. The mean frequencies in control vs. cancer were 6.97±1.49% vs. 6.89±2.49% at day 5, respectively and 5.38±0.73% vs. 4.90±1.19% at day 14, respectively; n = 8–10 at all time points.